Urinary Incontinence in Older Hong Kong Women: A Cross-sectional Study
NCT ID: NCT07243223
Last Updated: 2025-11-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
1100 participants
OBSERVATIONAL
2025-11-30
2027-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. To assess the epidemiological characteristics of urinary incontinence among older women, as well as patients' knowledge and healthcare-seeking barriers, and to explore factors influencing the disease subtypes, severity, and healthcare-seeking behaviors;
2. To establish diagnostic criteria for traditional Chinese medicine (TCM) syndrome differentiation of urinary incontinence, and analyze the distribution of TCM syndromes;
3. To explore diagnostic biomarkers and severity evaluation biomarkers for three subtypes of urinary incontinence (SUI, UUI, MUI).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acupuncture on Post-Stroke Overactive Bladder
NCT02568774
Acupuncture for Urinary Incontinence
NCT00297427
Efficacy of Conservative Treatments for Urinary Incontinence in Women
NCT05977231
Lessening Incontinence by Learning Yoga
NCT01672190
Optimized Acupuncture Treatment for Female Stress Urinary Incontinence
NCT05635669
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Both urinary incontinence group and healthy group will be recruited through a combination of online publicity (via social media platforms) and offline community outreach. Each participant will be scheduled for a visit, during which the research staff will introduce the study's objectives, procedures, nature, and data privacy policy. Informed consent will be obtained. Socio-epi-demographic information (including age, educational level, marital status, occupation, income, reproductive history, medical history, comorbidities, medication history, diagnosis and treatment for urinary incontinence) and the type, frequency and severity of lower urinary tract symptoms will be collected.
Then, eligible participants with symptoms of urinary incontinence will undergo a 1-hour pad test, bladder capacity and post-void residual volume measurements, and a 1-week bladder diary to confirm the subtype of urinary incontinence (SUI, MUI, UUI) and its severity (mild, moderate, severe). Standardized questionnaires will be administered to assess the cognitive level regarding urinary incontinence (UIQ), quality of life (IIQ-7 and ICIQ-UI-SF), and barriers to care seeking (Barriers to Incontinence Care Seeking Questionnaire). Hand grip strength test will be conducted to evaluate the muscle strength. The first 300 urinary incontinence patients (100 with SUI, 100 with UUI, and 100 with MUI) enrolled in the study, who do not have chronic comorbidities (except for well-controlled hypertension or hyperlipidemia) and are not taking medications that affect urination or gut microbiota, will proceed to TCM syndrome differentiation and bio-sample collection. TCM syndrome differentiation related symptoms and signs will be collected for Delphi consensus research and cluster analysis. Blood, urine, stool routine lab tests (including metabolic and inflammatory markers such as fasting blood glucose, fasting triglycerides, albumin, creatinine, glucose, C-reactive protein, white blood cell count, etc.) and biological sample collection will also be performed for these patients.
Eligible participants who have never experienced symptoms of urinary incontinence and have no chronic comorbidity (expect for well-controlled hypertension and hyperlipidemia) and are not taking medications that affect urination or gut microbiota will serve as healthy controls. For healthy group, only blood, urine, stool routine lab tests and bio-sample will be conducted.
All data will be independently collected and cross-verified by two researchers, and entered into the electronic data management system (REDCap).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Stress Urinary Incontinence (SUI)
Women diagnosed with SUI per EAU and ICS criteria: involuntary leakage during increased intra-abdominal pressure (e.g., exertion, coughing), stopping when the activity ends. Confirmed by positive cough stress or 1-hour pad test (\>1g leakage), and bladder diary showing stress-only leakage. Initial screening uses the Chinese 3IQ, option A ("leakage with physical activity"). Cases with urge or mixed symptoms are excluded. No intervention to be administered.
No interventions assigned to this group
Urge Urinary Incontinence (UUI)
Women diagnosed with UUI per EAU and ICS criteria: involuntary leakage of urine accompanied by or immediately preceded by urgency. Preliminary screening with Chinese 3IQ, option B ("leakage with urgency"). Final diagnosis confirmed by a bladder diary showing urgency-only leakage. Cases with stress or mixed symptoms are excluded. No intervention to be administered.
No interventions assigned to this group
Mixed Urinary Incontinence (MUI)
Women diagnosed with MUI per EAU and ICS guidelines: symptoms of both stress and urge urinary incontinence. Confirmed by positive 1-hour pad test (\>1g) and bladder diary showing both stress- and urgency-related leakage. Preliminary screening with Chinese 3IQ, option D ("leakage equally with activity and urgency"). Cases with pure stress or urge incontinence excluded. No intervention to be administered.
No interventions assigned to this group
Healthy Volunteers (HC)
Female volunteers aged ≥55, living in Hong Kong ≥1 year, no history or symptoms of urinary incontinence, no recent urological consultation, and no major comorbidities (except well-controlled hypertension/hyperlipidemia). Not using drugs affecting urination or the gut microbiota. Able to understand instructions and provide consent. Exclusions: UI diagnosis, involuntary urine leakage, severe illness interfering with assessment. No intervention to be administered.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Has been living in Hong Kong for one year or more.
3. Meet the diagnostic criteria for SUI, UUI, or MUI, and the symptoms of urinary incontinence have persisted for at least 6 months.
4. Able to understand and follow written and verbal instructions in Chinese or English.
5. Provide informed consent voluntarily after being fully informed
1. Female, aged ≥55 years;
2. Has been living in Hong Kong for one year or more;
3. Able to understand and follow written and verbal instructions in Chinese or English;
4. Fully informed and voluntarily signs the informed consent form.
Exclusion Criteria
1. Symptoms: Involuntary leakage of urine accompanied by or immediately preceded by urgency (a sudden, compelling desire to void that is difficult to defer).
2. Cases of pure stress urinary incontinence and mixed urinary incontinence will be excluded.
This subtype will be preliminarily identified using the Chinese version of the "3 Incontinence Questions" (3IQ): "During the past three months, in which of the following situations did you most often experience urine leakage? (single choice) A. During physical activities such as coughing, sneezing, lifting, or exercise; B. When you had the urge to urinate or felt the need to empty your bladder but could not reach the toilet in time; C. Without physical activity or urge; D. Equally during physical activity and urgency." (Selection of option B) Final confirmation will be based on a one-week bladder diary recorded by the participant (showing only urgency-related leakage).
4\. Mixed Urinary Incontinence (MUI):The clinical diagnosis of MUI will follow the guidelines of the European Association of Urology (EAU) and the International Continence Society (ICS):
1. Symptoms: The presence of stress urinary incontinence symptoms, such as involuntary leakage of urine during activities that increase intra-abdominal pressure (e.g., exercise, laughing, coughing, walking), with urine flow ceasing immediately upon stopping the activity; and, at the same time, the presence of urge urinary incontinence symptoms, such as urgency (a sudden, compelling desire to void that is difficult to defer) accompanied by or immediately followed by involuntary leakage of urine.
2. Signs: Positive result on the cough stress test or a positive 1-hour pad test (the procedure will follow the standardized protocol of the ICS; leakage \>1g is considered positive).
3. Cases of pure urge urinary incontinence and pure stress urinary incontinence will be excluded.
This subtype will be preliminarily identified using the Chinese version of the "3 Incontinence Questions" (3IQ): "During the past three months, in which of the following situations did you most often experience urine leakage? (single choice) A. During physical activities such as coughing, sneezing, lifting, or exercise; B. When you had the urge to urinate or felt the need to empty your bladder but could not reach the toilet in time; C. Without physical activity or urge; D. Equally during physical activity and urgency." (Selection of option D) Final confirmation will be based on a one-week bladder diary recorded by the participant (showing both urgency- and stress-related leakage) and a positive 1-hour pad test.
1. Diagnosed with types of urinary incontinence other than stress, urge, or mixed urinary incontinence, including those secondary to neurological or systemic diseases (such as post-stroke, post-spinal cord injury, multiple sclerosis, Alzheimer's disease, Parkinson's disease, or uncontrolled diabetic peripheral neuropathy), as well as the overflow incontinence.
2. Active or structural urogenital diseases (such as unrepaired vesicoureteral reflux, congenital urethral malformations, urogenital fistula, urethral diverticulum, or active pelvic malignancies).
3. Deemed by researchers to be unable to cooperate with assessments due to severe mental or physical illness.
7\. Eligible Urinary Incontinence Patients for Bio-Sample Collection
1. The first 300 urinary incontinence patients (100 each with SUI, UUI, and MUI) enrolled in the study.
2. No chronic comorbidities (except for well-controlled hypertension, defined as systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg, and hyperlipidemia), including neurological disorders (central nervous system injury, motor neuron diseases, neurodegenerative diseases), diabetes, connective tissue diseases, psychiatric disorders, severe cardiovascular or cerebrovascular diseases, and severe liver or kidney diseases.
3. Not using medications that affect urination or gut microbiota (including but not limited to thiazolidinediones, sodium-glucose cotransporter-2 inhibitors, anticholinergics, α- and β-adrenergic blockers, α- and β-adrenergic agonists, diuretic antihypertensives, antihistamines, muscarinic receptor antagonists, calcium channel blockers, angiotensin-converting enzyme inhibitors, hormone medications, neurotransmitter-related drugs, gut microbiota modulators, etc.).
1. Meet the diagnostic criteria for urinary incontinence;
2. Has a history of involuntary urine leakage, or has sought medical consultation for symptoms related to urinary incontinence;
3. Has chronic comorbidities (except for well-controlled hypertension, defined as systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg, and hyperlipidemia).
4. Uses medications that affect urination or gut microbiota (including but not limited to thiazolidinediones, sodium-glucose cotransporter-2 inhibitors, anticholinergics, α- and β-adrenergic blockers, α- and β-adrenergic agonists, diuretic antihypertensives, antihistamines, muscarinic receptor antagonists, calcium channel blockers, angiotensin-converting enzyme inhibitors, hormone medications, neurotransmitter-related drugs, and gut microbiota modulators, etc.).
5. Deemed by researchers to be unable to cooperate with assessments due to severe mental or physical illness.
55 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hong Kong Baptist University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ZhaoXiang Bian
Prof.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Qianqian Xu, MS, RCMP
Role: STUDY_DIRECTOR
Vincent V.C. Woo Chinese Medicine Clinical Research Institute, Hong Kong Baptist University
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REC/24-25/0631
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.